US Patent Issued to REGENRON PHARMACEUTICALS on April 22 for "Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy" (New York, New Jersey Inventors)

ALEXANDRIA, Va., June 6 -- United States Patent no. 12,280,093, issued on April 22, was assigned to REGENRON PHARMACEUTICALS INC. (Tarrytown, N.Y.).

"Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy" was invented by Robert L. Vitti (Old Tappan, N.J.), Alyson J. Berliner (New York) and Karen Chu (White Plains, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods for treating or preventing diabetic retinopathy, e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of a 2 mg aflibercept by...